8-K

                       SECURITIES AND EXCHANGE COMMISSION

                           Washington, D.C. 20549-1004

                                    FORM 8-K

                    CURRENT REPORT PURSUANT TO SECTION 13 OF

                       THE SECURITIES EXCHANGE ACT OF 1934

         Date of Report (date of earliest event reported): July 14, 2000

                          MIRAVANT MEDICAL TECHNOLOGIES

             (Exact name of Registrant as specified in its charter)

      Delaware                            0-2554                 77-0222872
(State or other jurisdiction of    Commission File Number)  (I.R.S. Employer
incorporation or organization)                            Identification Number)





                                336 Bollay Drive

                             Santa Barbara, CA 93117

                    (Address of principal executive offices)

                                 (805) 685-9880

              (Registrant's telephone number, including area code)





ITEM 5.  OTHER EVENTS

     On July 14, 2000,  Miravant  Medical  Technologies  issued a press  release
announcing that the Board of Directors of Miravant Medical Technologies approved
the  adoption  of a  Preferred  Stock  Rights  Agreement.  The press  release is
attached as Exhibit 99 to this Form 8-K.

ITEM 7.  FINANCIAL STATEMENTS AND EXHIBITS

          (c)         Exhibits.

          Exhibit 99  Miravant Medical Technologies Press Release issued
                      July 14, 2000.







                                    SIGNATURE

     Pursuant to the  requirements  of the Securities  Exchange Act or 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                        Miravant Medical Technologies
                                                 (Registrant)

Date:  July 14, 2000

                                        By:   /s/      John M. Philpott
                                              -------------------------
                                              Name:    John M. Philpott
                                              Title:   Chief Financial Officer





                                  EXHIBIT INDEX

Exhibit

Number

99       Miravant Medical Technologies Press Release issued July 14, 2000.

EX-99

SANTA BARBARA,  Calif., July 14, 2000 - Miravant Medical  Technologies  (Nasdaq:
MRVT)  announced  today that its Board of Directors has adopted a  Shareholders'
Rights  Plan.  Under the Plan,  Miravant  will issue a dividend of one right for
each share of its common  stock - par value of $0.001 per share - held after the
close of business on July 31, 2000. The Plan is designed to assure  stockholders
fair value in the event of a future unsolicited  business combination or similar
transaction  involving the Company. This Plan was not adopted in response to any
attempt to acquire the Company, and Miravant is not aware of any such efforts.

The rights will  become  exercisable  only if a person or group (i)  acquires 20
percent or more of  Miravant's  common stock,  or (ii)  announces a tender offer
that would result in ownership of 20 percent or more of the common  stock.  Each
right would  entitle a  stockholder  to buy a fractional  share of the Company's
preferred stock.  Each right has an initial exercise price of $180.00.  Once the
acquiring  person or group has  acquired  20 percent or more of the  outstanding
common stock of Miravant,  each right shall  entitle its holder  (other than the
acquiring  person or group) to  acquire  shares of the  company  or of the third
party acquirer having a value of twice the right's then-current exercise price.

The rights are  redeemable  at the option of the Board of Directors up until ten
days after public  announcement that any person or group has acquired 20 percent
or more of Miravant's  common stock.  The redemption  price is $0.001 per right.
The rights will expire on July 31,  2010,  unless  redeemed  prior to that date.
Distribution  of the rights is not taxable to  stockholders.  Further details of
the Plan are  outlined in a letter that will be sent to  stockholders  as of the
record date.

Miravant Medical  Technologies  specializes in both  pharmaceuticals and devices
for  photoselective   medicine.   The  Company  is  developing  its  proprietary
PhotoPoint  procedure in  ophthalmology,  oncology,  cardiovascular  disease and
other medical specialties.